Open, Prospective, Historic-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Infusion of Liver Cell Suspension (HHLivC) in Children With Urea Cycle Disorders
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2016
Price : $35 *
At a glance
- Drugs Liver cell therapy (Primary)
- Indications Inborn urea cycle disorders
- Focus Therapeutic Use
- Acronyms SELICA III
- Sponsors Cytonet; Promethera Biosciences
- 05 Feb 2016 Status changed from recruiting to discontinued as reported by cliinicaltrials.gov record.
- 09 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 according to cliinicaltrials.gov record.
- 09 Dec 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 according to cliinicaltrials.gov record.